文献速递消化系统肿瘤

胰腺癌中致癌性KRAS抑制的耐药机制

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.
PubMed 文献 · Cancer Discov · 2024-01-01

KRAS抑制剂在胰腺导管腺癌(PDAC)中显示临床疗效但耐药常见。接受阿达格拉西布或索托拉西布治疗的KRASG12C突变PDAC患者获得性耐药时出现PIK3CA和KRAS突变及KRASG12C、MYC、MET、EGFR、CDK6扩增。在PDAC细胞系和类器官中,上皮-间质转化和PI3K-AKT-mTOR信号与MRTX1133耐药相关;KPC小鼠模型经MRTX1133治疗获深度肿瘤消退但最终耐药,伴Kras、Yap1、Myc、Cdk6、Abcb1a/b扩增和耐药转录程序共进化;间质和基底样状态对KRAS抑制反应增加;KRASG12D抑制联合化疗显著改善肿瘤控制。

要点

  • KRASG12C突变PDAC患者对阿达格拉西布或索托拉西布获得性耐药时出现PIK3CA和KRAS突变及KRASG12C、MYC、MET、EGFR、CDK6扩增。
  • PDAC细胞系和类器官模型中,上皮-间质转化和PI3K-AKT-mTOR信号与MRTX1133耐药相关。
  • KPC小鼠模型经MRTX1133治疗获深度肿瘤消退但最终耐药,伴Kras、Yap1、Myc、Cdk6、Abcb1a/b扩增和耐药转录程序共进化。

核心结论

  • 这些数据阐明了KRAS抑制的共进化耐药机制并支持多种联合治疗策略。

研究设计与样本

  • 研究纳入接受阿达格拉西布或索托拉西布治疗的KRASG12C突变PDAC患者临床样本,并使用PDAC细胞系、类器官模型、KPC小鼠模型和PDX模型进行临床前研究。

主要发现

  • KRASG12C突变PDAC患者获得性耐药时出现PIK3CA和KRAS突变及KRASG12C、MYC、MET、EGFR、CDK6扩增。
  • PDAC细胞系和类器官模型中,上皮-间质转化和PI3K-AKT-mTOR信号与MRTX1133耐药相关。
  • KPC小鼠模型经MRTX1133治疗获深度肿瘤消退但最终耐药,伴Kras、Yap1、Myc、Cdk6、Abcb1a/b扩增和耐药转录程序共进化。
  • KPC和PDX模型中,间质和基底样细胞状态对KRAS抑制的反应较经典状态增加。
  • KRASG12D抑制联合化疗在PDAC小鼠模型中显著改善肿瘤控制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC); however, resistance is common. Among patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, mutations in PIK3CA and KRAS, and amplifications of KRASG12C, MYC, MET, EGFR, and CDK6 emerged at acquired resistance. In PDAC cell lines and organoid models treated with the KRASG12D inhibitor MRTX1133, epithelial-to-mesenchymal transition and PI3K-AKT-mTOR signaling associate with resistance to therapy. MRTX1133 treatment of the KrasLSL-G12D/+; Trp53LSL-R172H/+; p48-Cre (KPC) mouse model yielded deep tumor regressions, but drug resistance ultimately emerged, accompanied by amplifications of Kras, Yap1, Myc, Cdk6, and Abcb1a/b, and co-evolution of drug-resistant transcriptional programs. Moreover, in KPC and PDX models, mesenchymal and basal-like cell states displayed increased response to KRAS inhibition compared to the classical state. Combination treatment with KRASG12D inhibition and chemotherapy significantly improved tumor control in PDAC mouse models. Collectively, these data elucidate co-evolving resistance mechanisms to KRAS inhibition and support multiple combination therapy strategies. Significance: Acquired resistance may limit the impact of KRAS inhibition in patients with PDAC. Using clinical samples and multiple preclinical models, we define heterogeneous genetic and non-genetic mechanisms of resistance to KRAS inhibition that may guide combination therapy approaches to improve the efficacy and durability of these promising therapies for patients. See related commentary by Marasco and Misale, p. 2018.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Dilly J, Hoffman MT, Abbassi L, et al. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Cancer Discov. 2024. PMID: 38975874. doi:10.1158/2159-8290.CD-24-0177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。